Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, shared on X:
“FOURLIGHT-1 beautifully presented by Antonio Giordano.
Fulvestrant + atirmociclib (cdk4i) vs Fulvestrant or exemestane + everolimus.
All had prior CDK 4/6i PFS 9.9 vs 6.6 HR 0.60 p=0.0007.”
You can also read:
FOURLIGHT-1: Atirmociclib Reduces Progression Risk After Prior CDK4/6 Inhibition
